Management of COVID-19 in cancer patients receiving cardiotoxic anti-cancer therapy.: Future recommendations for cardio-oncology

Hasan Kobat; Islam Elkonaissi; Mehmet Tevfik Dorak; Shereen Nabhani-Gebara

doi:10.4081/oncol.2021.510

Management of COVID-19 in cancer patients receiving cardiotoxic anti-cancer therapy. Future recommendations for cardio-oncology

Hasan Kobat
, Islam Elkonaissi
, Mehmet Tevfik Dorak
, Shereen Nabhani-Gebara

Kingston University
Cambridge University Hospitals NHS Foundation Trust

Research output: Contribution to journal › Article › peer-review

5 Downloads (Pure)

Abstract

Cardiotoxicity induced by anti-cancer treatment has become a significant threat as the number of cardiotoxic anti-cancer agents is growing. Cancer patients are at an increased risk of contracting coronavirus disease 2019 (COVID-19) because of immune suppression caused by anti-cancer drugs and/or supportive treatment. Deterioration in lung functions due to COVID-19 is responsible for many cardiac events. The presence of COVID-19 and some of its treatment modalities may increase the chance of cardiotoxicity development in cancer patients receiving potentially cardiotoxic agents. This review provides evidence-based information on the cardiotoxicity risk in cancer patients clinically diagnosed with COVID-19 who are receiving potentially cardiotoxic anti-cancer agents. Proposed strategies relating to the management of this patient cohorts are also discussed.

Original language	English
Article number	510
Journal	Oncology Reviews
Volume	15
Issue number	1
Early online date	26 Feb 2021
DOIs	https://doi.org/10.4081/oncol.2021.510
Publication status	Published - 2021

Keywords

Cancer studies

Access to Document

10.4081/oncol.2021.510Licence: CC BY-NC

Kobat-H-48474-VoRFinal published version, 954 KBLicence: CC BY-NC

Cardiotoxicities of Systemic Anti-Cancer Therapies
El Nabhani, S. (PI)
6/05/19 → 22/07/24
Project: Research

Cite this

@article{da040263d45e466289ab46fc0ebb6754,

title = "Management of COVID-19 in cancer patients receiving cardiotoxic anti-cancer therapy.: Future recommendations for cardio-oncology",

abstract = "Cardiotoxicity induced by anti-cancer treatment has become a significant threat as the number of cardiotoxic anti-cancer agents is growing. Cancer patients are at an increased risk of contracting coronavirus disease 2019 (COVID-19) because of immune suppression caused by anti-cancer drugs and/or supportive treatment. Deterioration in lung functions due to COVID-19 is responsible for many cardiac events. The presence of COVID-19 and some of its treatment modalities may increase the chance of cardiotoxicity development in cancer patients receiving potentially cardiotoxic agents. This review provides evidence-based information on the cardiotoxicity risk in cancer patients clinically diagnosed with COVID-19 who are receiving potentially cardiotoxic anti-cancer agents. Proposed strategies relating to the management of this patient cohorts are also discussed.",

keywords = "Cancer studies",

author = "Hasan Kobat and Islam Elkonaissi and Dorak, \{Mehmet Tevfik\} and Shereen Nabhani-Gebara",

year = "2021",

doi = "10.4081/oncol.2021.510",

language = "English",

volume = "15",

journal = "Oncology Reviews",

issn = "1970-5557",

publisher = "Frontiers Media SA",

number = "1",

}

TY - JOUR

T1 - Management of COVID-19 in cancer patients receiving cardiotoxic anti-cancer therapy.

T2 - Future recommendations for cardio-oncology

AU - Kobat, Hasan

AU - Elkonaissi, Islam

AU - Dorak, Mehmet Tevfik

AU - Nabhani-Gebara, Shereen

PY - 2021

Y1 - 2021

N2 - Cardiotoxicity induced by anti-cancer treatment has become a significant threat as the number of cardiotoxic anti-cancer agents is growing. Cancer patients are at an increased risk of contracting coronavirus disease 2019 (COVID-19) because of immune suppression caused by anti-cancer drugs and/or supportive treatment. Deterioration in lung functions due to COVID-19 is responsible for many cardiac events. The presence of COVID-19 and some of its treatment modalities may increase the chance of cardiotoxicity development in cancer patients receiving potentially cardiotoxic agents. This review provides evidence-based information on the cardiotoxicity risk in cancer patients clinically diagnosed with COVID-19 who are receiving potentially cardiotoxic anti-cancer agents. Proposed strategies relating to the management of this patient cohorts are also discussed.

AB - Cardiotoxicity induced by anti-cancer treatment has become a significant threat as the number of cardiotoxic anti-cancer agents is growing. Cancer patients are at an increased risk of contracting coronavirus disease 2019 (COVID-19) because of immune suppression caused by anti-cancer drugs and/or supportive treatment. Deterioration in lung functions due to COVID-19 is responsible for many cardiac events. The presence of COVID-19 and some of its treatment modalities may increase the chance of cardiotoxicity development in cancer patients receiving potentially cardiotoxic agents. This review provides evidence-based information on the cardiotoxicity risk in cancer patients clinically diagnosed with COVID-19 who are receiving potentially cardiotoxic anti-cancer agents. Proposed strategies relating to the management of this patient cohorts are also discussed.

KW - Cancer studies

U2 - 10.4081/oncol.2021.510

DO - 10.4081/oncol.2021.510

M3 - Article

SN - 1970-5557

VL - 15

JO - Oncology Reviews

JF - Oncology Reviews

IS - 1

M1 - 510

ER -

Management of COVID-19 in cancer patients receiving cardiotoxic anti-cancer therapy. Future recommendations for cardio-oncology

Abstract

Keywords

Access to Document

Fingerprint

Projects

Cardiotoxicities of Systemic Anti-Cancer Therapies

Cite this